- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00532883
Hydroxyurea and Magnesium Pidolate to Treat People With Hemoglobin Sickle Cell Disease
Effectiveness of Hydroxyurea and Magnesium Pidolate Alone and in Combination in Hemoglobin SC Disease: A Phase II Trial
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
SCD is an inherited blood disorder. Symptoms include anemia, infections, organ damage, and intense episodes of pain, which are called "sickle cell crises." SCD is caused by an abnormal type of hemoglobin, which is a protein inside red blood cells that carries oxygen. HbSC is a form of SCD that is characterized by the presence of dense red blood cells. People with HbSC usually develop less severe SCD symptoms than people with the more common form of the disease. There are limited treatment approaches aimed specifically at modifying the abnormal state of red blood cells. Also, few combination therapy treatments have been studied. The medication hydroxyurea is currently used to prevent sickle cell crises and to decrease the need for blood transfusions. The dietary supplement magnesium has not been widely studied as a treatment for SCD, but it may prevent dehydration, which may decrease the frequency of sickle cell crises. The purpose of this study is to evaluate the safety and effectiveness of hydroxyurea and magnesium pidolate, alone and combined, at reducing red blood cell density and the frequency of sickle cell crises in people with HbSC.
This 1-year study will enroll people with HbSC. Participants will be randomly assigned to one of the following four treatment groups:
- Group 1 participants will receive placebo pills and placebo liquid.
- Group 2 participants will receive hydroxyurea pills and placebo liquid.
- Group 3 participants will receive placebo pills and magnesium pidolate liquid.
- Group 4 participants will receive hydroxyurea pills and magnesium pidolate liquid.
Participants will receive the hydroxyurea or placebo pills once a day and the magnesium pidolate or placebo liquid twice a day for 11 months. Study visits will occur every 2 weeks during the first 2 months of the study, once a month for the following 9 months, and then at Year 1. At each visit, a physical exam and blood collection will occur. Selected visits will also include urine collection and a pregnancy test for female participants. Throughout the study, participants will record their study medication use in a daily diary.
Study Type
Enrollment (Actual)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
Alabama
-
Birmingham, Alabama, United States, 35233
- University of Alabama at Birmingham
-
-
California
-
Oakland, California, United States, 94609-1809
- Children's Hospital and Research Center
-
Sacramento, California, United States, 95817
- University of California Davis
-
-
Colorado
-
Aurora, Colorado, United States, 80045
- University of Colorado
-
-
Florida
-
Miami, Florida, United States, 33136
- University of Miami
-
-
Georgia
-
Atlanta, Georgia, United States, 30342-1600
- Children's Healthcare of Atlanta
-
-
Kentucky
-
Louisville, Kentucky, United States, 40202
- University of Louisville
-
-
Maryland
-
Baltimore, Maryland, United States, 21205
- Johns Hopkins University
-
-
Massachusetts
-
Boston, Massachusetts, United States, 02118
- Boston Medical Center
-
Boston, Massachusetts, United States, 02118
- Children's Hospital Boston
-
-
Mississippi
-
Jackson, Mississippi, United States, 39216
- University of Mississippi Medical Center
-
-
New York
-
Bronx, New York, United States, 10463
- Montefiore Medical Center
-
-
North Carolina
-
Durham, North Carolina, United States, 27710
- Duke University Medical Center
-
-
Ohio
-
Cincinnati, Ohio, United States, 45229
- Cincinnati CHildren's Hospital
-
-
Oklahoma
-
Oklahoma City, Oklahoma, United States, 73104
- University of Oklahoma
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, United States, 19444
- Children's Hospital of Philadelphia
-
Philadelphia, Pennsylvania, United States, 19134-1095
- Saint Christopher's Hospital
-
-
Tennessee
-
Memphis, Tennessee, United States, 38105
- St. Jude Children's Research Hospital
-
-
Texas
-
Dallas, Texas, United States, 75235
- Children's Medical Center
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Diagnosis of HbSC disease
- Hemoglobin level between 8 and 12.5 g/dL
- At least one vaso-occlusive event (e.g., pain, acute chest syndrome) in the 12 months prior to study entry. An episode of pain is defined as the occurrence of pain in the extremities, back, abdomen, chest, or head that lasts at least 2 hours; requires a visit to a hospital, emergency room, clinic, or provider's office; and is not explained except by SCD. Acute chest syndrome is defined as a new pulmonary infiltrate on a chest x-ray associated with a fever (greater than 38.5° C), tachypnea, wheezing, cough, or chest pain.
- Regular compliance with comprehensive care
- In a steady disease state and not experiencing an acute complication of SCD (i.e., no hospitalization, pain event, or episode of acute chest syndrome within the 1 month prior to study entry)
Exclusion Criteria:
- Previous transfusion with remaining hemoglobin A greater than 10%
- Previous treatment with hydroxyurea within the last 3 months
- Previous treatment with magnesium within the 3 months prior to study entry (including vitamins containing magnesium)
- Poor compliance with previous treatment regimens
- Liver dysfunction (SGPT greater than twice the upper limit of normal) within the 1 month prior to study entry
- Kidney dysfunction (creatinine greater than or equal to 1.0 mg/dL for participants less than 18 years of age; greater than or equal to 1.2 mg/dL for participants 18 years of age or older) within the 1 month prior to study entry
- Pregnant
- Ten or more hospital admissions for pain in the 12 months prior to study entry
- Daily use of narcotics
- Treatment with any investigational drug in the 3 months prior to study entry
- Less than 3% red blood cells with density greater than 41 g/dL (as measured by the ADVIA 120 system)
- Positive HIV test
- Other long-term illness or disorder other than SCD that could adversely affect performance in the study (e.g., tuberculosis)
Study Plan
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: QUADRUPLE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
PLACEBO_COMPARATOR: Placebo Pills and Placebo Liquid
|
HU/Placebo capsules (20 mg/kg/day for 11 months) Mg/Placebo liquid (0.6 mEq/kg/day for 11 months)
|
ACTIVE_COMPARATOR: Hydroxyurea Pills and Placebo Liquid
|
HU capsules (20 mg/kg/day for 11 months) Mg/Placebo liquid (0.6 mEq/kg/day for 11 months)
|
ACTIVE_COMPARATOR: Placebo Pills and Magnesium Pidolate Liquid
|
HU/Placebo capsules (20 mg/kg/day for 11 months) Mg liquid (0.6 mEq/kg/day for 11 months)
|
ACTIVE_COMPARATOR: Hydroxyurea Pills and Magnesium Pidolate Liquid
|
HU capsules (20 mg/kg/day for 11 months) Mg/Placebo liquid (0.6 mEq/kg/day for 11 months)
HU/Placebo capsules (20 mg/kg/day for 11 months) Mg liquid (0.6 mEq/kg/day for 11 months)
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Distribution of the Density of Hemoglobin SC Red Cells
Time Frame: measured 2 months after initiation of treatment
|
An individuals' percentage of red blood cells with density greater than 41 g/dL as measured by Advia.
|
measured 2 months after initiation of treatment
|
Collaborators and Investigators
Collaborators
Investigators
- Principal Investigator: Winfred C. Wang, MD, St. Jude Children's Research Hospital
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Primary Completion (ACTUAL)
Study Completion (ACTUAL)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ESTIMATE)
Study Record Updates
Last Update Posted (ESTIMATE)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Hematologic Diseases
- Genetic Diseases, Inborn
- Anemia
- Anemia, Hemolytic, Congenital
- Anemia, Hemolytic
- Hemoglobinopathies
- Anemia, Sickle Cell
- Hemoglobin SC Disease
- Molecular Mechanisms of Pharmacological Action
- Nucleic Acid Synthesis Inhibitors
- Enzyme Inhibitors
- Antineoplastic Agents
- Antisickling Agents
- Hydroxyurea
Other Study ID Numbers
- CHAMPS-St. Jude
- U54HL070587 (U.S. NIH Grant/Contract)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Hemoglobin SC Disease
-
Emory UniversityPatient-Centered Outcomes Research InstituteCompletedSickle Cell Disease | Sickle Cell Anemia | Hemoglobin SC | Hemoglobin SS | Hemoglobin Beta ThalassemiaUnited States
-
Baylor College of MedicineBoston Children's HospitalTerminated
-
Tami D. JohnBaylor College of Medicine; The Methodist Hospital Research InstituteTerminatedSickle Cell Disease | Hemoglobin SCUnited States
-
Centre Hospitalier Universitaire de Saint EtienneClaude Bernard University; Laboratoire de Physiologie de l'Exercice; Centre de...CompletedHemoglobin S Disease | Sickle Cell Hemoglobin C DiseaseFrance
-
Sidney Kimmel Cancer Center at Thomas Jefferson...National Heart, Lung, and Blood Institute (NHLBI)TerminatedSickle Cell Anemia | Sickle Cell-hemoglobin C Disease | Sickle Cell-β0-thalassemiaUnited States
-
SangartCompletedSickle Cell Disease | Anemia, Sickle Cell | Sickle Cell Anemia | Hemoglobin SC Disease | Sickle Cell Disorders | Sickle Cell Hemoglobin C DiseaseUnited Kingdom, France, Jamaica, Lebanon
-
Klein Buendel, Inc.National Institute on Minority Health and Health Disparities (NIMHD); Hilton...CompletedSickle Cell Disease | Sickle Cell Anemia in Children | Sickle Cell Thalassemia | Sickle Cell SC DiseaseUnited States
-
Nova Laboratories LimitedCompletedSickle Cell Disease | Sickle Cell Hemoglobin C | Sickle Cell-beta-thalassemia | Sickle-Cell; Hemoglobin Disease, ThalassemiaUnited Kingdom, Jamaica
-
SangartWithdrawnSickle Cell Disease | Anemia, Sickle Cell | Sickle Cell Anemia | Hemoglobin SC Disease | Sickle Cell Disorders | Sickle Cell Hemoglobin C DiseaseFrance, United Kingdom, Netherlands, Turkey, Bahrain, Belgium, Brazil, Lebanon, Qatar
-
Aga Khan UniversityUnknownHyperglycemia | Anemia | Dyslipidemias | Oxidative Stress | Liver Dysfunction | Hemoglobin SCPakistan
Clinical Trials on Placebo Pills and Placebo Liquid
-
Singapore Institute of TechnologyAMILI Pte. Ltd.Active, not recruitingGastrointestinal Microbiome | Protein DigestionSingapore
-
Beijing Tiantan HospitalTasly Pharmaceutical Group Co., LtdActive, not recruiting
-
Virginia Commonwealth UniversityCompleted
-
University of Maryland, BaltimoreNot yet recruitingChronic Pain | Headache
-
Tasly Pharmaceutical Group Co., LtdCompleted
-
Tasly Pharmaceuticals, Inc.UnknownNon-small Cell Lung Cancer (NSCLC)China
-
Dalian UniversityUnknown
-
Dongzhimen Hospital, BeijingNot yet recruiting
-
Chonbuk National University HospitalCompletedHyperlipidemiaKorea, Republic of